Cargando…

Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B

BACKGROUND: Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of treatment response in both interferon-α and nucleoside analogue therapies. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Min-ran, Zheng, Huan-wei, Lu, Jian-hua, Ma, Shun-mao, Ye, Li-hong, Liu, Zhi-quan, Zhang, Hai-cong, Liu, Yun-yan, Lv, Ying, Huang, Yan, Dai, Er-hei, Sun, Dian-xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355246/
https://www.ncbi.nlm.nih.gov/pubmed/28052021
http://dx.doi.org/10.18632/oncotarget.14323
_version_ 1782515509888024576
author Li, Min-ran
Zheng, Huan-wei
Lu, Jian-hua
Ma, Shun-mao
Ye, Li-hong
Liu, Zhi-quan
Zhang, Hai-cong
Liu, Yun-yan
Lv, Ying
Huang, Yan
Dai, Er-hei
Sun, Dian-xing
author_facet Li, Min-ran
Zheng, Huan-wei
Lu, Jian-hua
Ma, Shun-mao
Ye, Li-hong
Liu, Zhi-quan
Zhang, Hai-cong
Liu, Yun-yan
Lv, Ying
Huang, Yan
Dai, Er-hei
Sun, Dian-xing
author_sort Li, Min-ran
collection PubMed
description BACKGROUND: Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of treatment response in both interferon-α and nucleoside analogue therapies. However, few data have been published regarding the relationship between quantitative anti-HBc (qAnti-HBc) levels and liver fibrosis in patients with CHB. RESULTS: A total of 489 HBeAg-positive (HBeAg (+)) and 135 HBeAg-negative (HBeAg (−)) patients were recruited. In both HBeAg (+) and HBeAg (−) groups, the S0−1/S0 subjects had significantly lower qAnti-HBc levels than the S2−4 subjects (p < 0.05). Multiple logistic regression analysis showed that the parameters for predicting significant fibrosis (S ≥ 2) included age, PLT and qAnti-HBc. In HBeAg (+) subjects, the AUROC of qAnti-HBc for predicting significant fibrosis was 0.734 (95% CI 0.689 to 0.778) and the optimal cut-off was 4.58 log10IU/mL, with a sensitivity of 63.08% and a specificity of 74.83%. In HBeAg (−) subjects, the AUROC was 0.707 (95% CI 0.612 to 0.801) and the optimal cut-off value was 4.37 log10IU/mL, with a sensitivity of 75.53% and a specificity of 56.10%. MATERIALS AND METHODS: From 2012 to 2015, we conducted a cross-sectional study of treatment-naïve CHB patients. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, hepatitis B surface antigen (HBsAg) titers and HBV genotype were determined using commercial assays, and serum qAnti-HBc levels were measured using double-sandwich immunoassay. Liver biopsies and serum samples were obtained on the same day. CONCLUSIONS: The present study showed an association between high serum qAnti-HBc levels and significant fibrosis (S ≥ 2) in treatment-naïve CHB patients. Furthermore, we described a serum qAnti-HBc cut-off for predicting significant fibrosis in CHB patients infected with HBV genotype B or C.
format Online
Article
Text
id pubmed-5355246
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53552462017-04-26 Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B Li, Min-ran Zheng, Huan-wei Lu, Jian-hua Ma, Shun-mao Ye, Li-hong Liu, Zhi-quan Zhang, Hai-cong Liu, Yun-yan Lv, Ying Huang, Yan Dai, Er-hei Sun, Dian-xing Oncotarget Research Paper BACKGROUND: Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predictor of treatment response in both interferon-α and nucleoside analogue therapies. However, few data have been published regarding the relationship between quantitative anti-HBc (qAnti-HBc) levels and liver fibrosis in patients with CHB. RESULTS: A total of 489 HBeAg-positive (HBeAg (+)) and 135 HBeAg-negative (HBeAg (−)) patients were recruited. In both HBeAg (+) and HBeAg (−) groups, the S0−1/S0 subjects had significantly lower qAnti-HBc levels than the S2−4 subjects (p < 0.05). Multiple logistic regression analysis showed that the parameters for predicting significant fibrosis (S ≥ 2) included age, PLT and qAnti-HBc. In HBeAg (+) subjects, the AUROC of qAnti-HBc for predicting significant fibrosis was 0.734 (95% CI 0.689 to 0.778) and the optimal cut-off was 4.58 log10IU/mL, with a sensitivity of 63.08% and a specificity of 74.83%. In HBeAg (−) subjects, the AUROC was 0.707 (95% CI 0.612 to 0.801) and the optimal cut-off value was 4.37 log10IU/mL, with a sensitivity of 75.53% and a specificity of 56.10%. MATERIALS AND METHODS: From 2012 to 2015, we conducted a cross-sectional study of treatment-naïve CHB patients. Liver biochemistry, hepatitis B virus (HBV) serological markers, HBV DNA, hepatitis B surface antigen (HBsAg) titers and HBV genotype were determined using commercial assays, and serum qAnti-HBc levels were measured using double-sandwich immunoassay. Liver biopsies and serum samples were obtained on the same day. CONCLUSIONS: The present study showed an association between high serum qAnti-HBc levels and significant fibrosis (S ≥ 2) in treatment-naïve CHB patients. Furthermore, we described a serum qAnti-HBc cut-off for predicting significant fibrosis in CHB patients infected with HBV genotype B or C. Impact Journals LLC 2016-12-28 /pmc/articles/PMC5355246/ /pubmed/28052021 http://dx.doi.org/10.18632/oncotarget.14323 Text en Copyright: © 2017 Li et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Li, Min-ran
Zheng, Huan-wei
Lu, Jian-hua
Ma, Shun-mao
Ye, Li-hong
Liu, Zhi-quan
Zhang, Hai-cong
Liu, Yun-yan
Lv, Ying
Huang, Yan
Dai, Er-hei
Sun, Dian-xing
Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B
title Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B
title_full Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B
title_fullStr Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B
title_full_unstemmed Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B
title_short Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B
title_sort serum hepatitis b core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis b
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355246/
https://www.ncbi.nlm.nih.gov/pubmed/28052021
http://dx.doi.org/10.18632/oncotarget.14323
work_keys_str_mv AT liminran serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT zhenghuanwei serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT lujianhua serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT mashunmao serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT yelihong serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT liuzhiquan serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT zhanghaicong serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT liuyunyan serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT lvying serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT huangyan serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT daierhei serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb
AT sundianxing serumhepatitisbcoreantibodytiteruseinscreeningforsignificantfibrosisintreatmentnaivepatientswithchronichepatitisb